^
Association details:
| Biomarker: | HR positive + HER-2 positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Drug Class: | Aromatase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Published date:
08/21/2020
Excerpt:
Dual HER2 blockade with LAP plus TRAS plus AI showed superior PFS benefit versus TRAS plus AI in patients with HER2-positive/HR-positive MBC.
DOI:
10.1200/JCO.20.01894
